Transferrin Isoform Detection for Alzheimer's Early Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic markers for Alzheimer's disease are insufficient for early detection and differential diagnosis, particularly in distinguishing it from other types of dementia, as they lack specificity and sensitivity, especially in the early stages of the disease.
Innovation Solution
A diagnostic kit that quantitatively detects transferrin with varying numbers of sialic acids attached to its sugar chains in cerebrospinal and blood samples, using a lectin enzyme-linked immunosorbent assay, to identify specific quantitative changes indicative of Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic markers are used for Alzheimer's disease diagnosis, then diagnosis can be performed, but early detection and differential diagnosis capability is insufficient
Solution Approach 1:
The patent changes the diagnostic parameter from general Alzheimer's markers to specific transferrin isoforms with different sialic acid contents (Tf1, Tf2, Tf3, Tf4). This parameter change enables early detection by identifying specific glycosylation pattern alterations that occur before clinical symptoms manifest, while maintaining diagnostic accuracy through the specific ratio analysis of these isoforms.
2Measurement precision
If clinical diagnosis methods are used, then diagnosis can be performed, but differentiation from other types of dementia is difficult
Solution Approach 1:
The patent extracts and measures specific transferrin isoforms (Tf1-Tf4) with defined sialic acid contents from the complex cerebrospinal fluid proteome. By focusing on this specific subset of proteins with distinct glycosylation patterns, the method achieves differential diagnosis capability to distinguish Alzheimer's disease from other dementias while maintaining relative simplicity through targeted quantification of these extracted markers.
3Measurement precision
If early diagnosis is achieved through detailed medical interviews and examinations, then diagnosis can be performed, but reliance on specialist judgment increases and objective measurement decreases
Solution Approach 1:
The patent replaces the mechanical system of specialist judgment and subjective clinical assessment with an objective biochemical measurement system. By quantifying the ratios of transferrin isoforms (Tf1-Tf4) with specific sialic acid contents, the method provides automated, objective diagnostic data that reduces dependency on specialist interpretation while enhancing measurement precision through standardized biochemical assays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate early-stage diagnosis of Alzheimer's disease and differential diagnosis from other dementias, enabling effective treatment planning and reducing the burden of misdiagnosis.
Implementation Method 1
a detection means for quantitatively detecting transferrin having a sugar chain with a varying number of sialic acids attached thereto
Implementation Method 2
lectin enzyme-linked immunosorbent assay
Implementation Method 3
enzyme-linked immunosorbent assay
Data Source
AI summary
While the differential diagnosis of Alzheimer's disease as distinguished from other types of dementia and the diagnosis of Alzheimer's disease at an early stage where neuronal apoptosis has not proceeded yet are important for the treatment of Alzheimer's disease, it is difficult to differentially diagnose Alzheimer's disease at early stage via a diagnosis mainly made by questioning by a doctor or a diagnostic technique using phosphorylated tau or amyloid β-protein as an indicator. Accordingly, the development of a novel diagnostic technique has been desired. Thus, according to the present invention, by focusing on a transferrin having a sugar chain attached thereto, a diagnostic kit, a diagnostic marker, and a detection means for differentially diagnosing the disease condition of Alzheimer's disease at an early stage are provided.